Yield10 Historical Balance Sheet

YTEN Stock

USD 0.23 0.03 11.54%

Trend analysis of Yield10 Bioscience balance sheet accounts such as Total Assets of 3.7 M, Other Assets of 361.6 K, Common Stock Shares Outstanding of 8.3 M or Liabilities And Stockholders Equity of 3.7 M provides information on Yield10 Bioscience's total assets, liabilities, and equity, which is the actual value of Yield10 Bioscience to its prevalent stockholders. By breaking down trends over time using Yield10 Bioscience balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Yield10 Bioscience latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Yield10 Bioscience is a good buy for the upcoming year.

Yield10 Bioscience Inventory

0.86

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Yield10 Bioscience. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Yield10 Stock, please use our How to Invest in Yield10 Bioscience guide.

About Yield10 Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Yield10 Bioscience at a specified time, usually calculated after every quarter, six months, or one year. Yield10 Bioscience Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Yield10 Bioscience and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Yield10 currently owns. An asset can also be divided into two categories, current and non-current.

Yield10 Bioscience Balance Sheet Chart

Yield10 Bioscience Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Yield10 Bioscience uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Yield10 Bioscience's Short Term Debt is very stable compared to the past year. As of the 25th of April 2024, Common Stock is likely to grow to about 185.2 K, while Total Assets are likely to drop about 3.7 M.

Other Assets Common Stock Shares Outstanding Other Stockholder Equity Total Liab

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from Yield10 Bioscience's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Yield10 Bioscience current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Yield10 Bioscience. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Yield10 Stock, please use our How to Invest in Yield10 Bioscience guide.At this time, Yield10 Bioscience's Short Term Debt is very stable compared to the past year. As of the 25th of April 2024, Common Stock is likely to grow to about 185.2 K, while Total Assets are likely to drop about 3.7 M.

	2021	2022	2023	2024 (projected)
Total Liabilities	4.4M	3.7M	6.4M	6.1M
Other Stockholder Equity	402.3M	404.3M	411.8M	282.7M

Total Liab Other Stockholder Equity

Yield10 Bioscience balance sheet Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant And Equipment Gross
Total Assets		0.91	-0.03	-0.28	-0.3	0.25	0.71	-0.17	0.58	0.67	0.64	-0.08	0.86	-0.66	-0.15	0.71	0.3	0.2	0.93	0.57	0.31	0.89	0.05	0.29	0.36	-0.08
Total Stockholder Equity	0.91		-0.11	-0.27	-0.29	0.35	0.36	-0.22	0.65	0.6	0.27	-0.21	0.63	-0.68	-0.2	0.72	0.17	0.25	0.78	0.65	0.4	0.7	-0.28	0.45	0.46	-0.25
Retained Earnings	-0.03	-0.11		0.4	-0.55	-0.93	0.12	-0.55	0.15	0.34	0.24	-0.39	0.25	-0.37	0.49	0.3	-0.2	0.46	0.3	0.53	0.15	0.27	0.72	0.34	0.02	-0.48
Other Assets	-0.28	-0.27	0.4		-0.28	-0.41	-0.17	-0.18	-0.13	-0.16	-0.09	-0.1	-0.14	0.07	-0.01	-0.13	-0.1	0.36	-0.13	0.01	-0.1	-0.12	0.28	-0.07	0.02	-0.01
Common Stock Shares Outstanding	-0.3	-0.29	-0.55	-0.28		0.33	-0.2	0.31	-0.34	-0.2	-0.27	0.14	-0.24	0.6	0.3	-0.62	-0.06	-0.73	-0.4	-0.52	-0.37	-0.25	-0.28	-0.31	-0.35	0.51
Other Stockholder Equity	0.25	0.35	-0.93	-0.41	0.33		-0.05	0.45	0.0	-0.18	-0.16	0.32	-0.1	0.15	-0.62	-0.07	0.22	-0.29	-0.09	-0.32	-0.02	-0.09	-0.72	-0.21	0.13	0.39
Total Liab	0.71	0.36	0.12	-0.17	-0.2	-0.05		0.0	0.19	0.49	0.98	0.18	0.88	-0.33	-0.01	0.38	0.39	0.03	0.77	0.18	0.02	0.81	0.59	-0.13	0.03	0.25
Short Long Term Debt Total	-0.17	-0.22	-0.55	-0.18	0.31	0.45	0.0		-0.61	-0.52	-0.1	0.93	-0.25	0.71	-0.26	-0.59	0.73	-0.55	-0.35	-0.52	-0.38	-0.21	-0.18	-0.36	-0.31	0.51
Other Current Liab	0.58	0.65	0.15	-0.13	-0.34	0.0	0.19	-0.61		0.82	0.13	-0.7	0.41	-0.86	0.08	0.84	-0.44	0.55	0.52	0.78	0.6	0.38	-0.23	0.66	0.77	-0.56
Total Current Liabilities	0.67	0.6	0.34	-0.16	-0.2	-0.18	0.49	-0.52	0.82		0.44	-0.55	0.7	-0.73	0.43	0.7	-0.21	0.33	0.72	0.79	0.4	0.68	0.16	0.6	0.51	-0.34
Other Liab	0.64	0.27	0.24	-0.09	-0.27	-0.16	0.98	-0.1	0.13	0.44		0.12	0.85	-0.34	0.0	0.37	0.33	0.09	0.76	0.16	0.01	0.78	0.7	-0.18	-0.03	0.21
Property Plant And Equipment Net	-0.08	-0.21	-0.39	-0.1	0.14	0.32	0.18	0.93	-0.7	-0.55	0.12		-0.08	0.67	-0.31	-0.56	0.86	-0.47	-0.19	-0.51	-0.5	-0.03	0.07	-0.43	-0.45	0.55
Current Deferred Revenue	0.86	0.63	0.25	-0.14	-0.24	-0.1	0.88	-0.25	0.41	0.7	0.85	-0.08		-0.54	0.09	0.56	0.27	0.17	0.94	0.48	0.1	0.96	0.47	0.14	0.16	-0.03
Net Debt	-0.66	-0.68	-0.37	0.07	0.6	0.15	-0.33	0.71	-0.86	-0.73	-0.34	0.67	-0.54		0.07	-0.99	0.4	-0.59	-0.71	-0.77	-0.68	-0.52	-0.06	-0.52	-0.66	0.6
Accounts Payable	-0.15	-0.2	0.49	-0.01	0.3	-0.62	-0.01	-0.26	0.08	0.43	0.0	-0.31	0.09	0.07		-0.14	-0.17	-0.18	0.04	0.27	-0.09	0.12	0.35	0.31	-0.23	-0.08
Cash	0.71	0.72	0.3	-0.13	-0.62	-0.07	0.38	-0.59	0.84	0.7	0.37	-0.56	0.56	-0.99	-0.14		-0.3	0.54	0.73	0.75	0.68	0.54	0.03	0.5	0.67	-0.57
Non Current Assets Total	0.3	0.17	-0.2	-0.1	-0.06	0.22	0.39	0.73	-0.44	-0.21	0.33	0.86	0.27	0.4	-0.17	-0.3		-0.23	0.21	-0.14	-0.39	0.36	0.15	-0.2	-0.36	0.42
Non Currrent Assets Other	0.2	0.25	0.46	0.36	-0.73	-0.29	0.03	-0.55	0.55	0.33	0.09	-0.47	0.17	-0.59	-0.18	0.54	-0.23		0.28	0.51	0.41	0.12	0.09	0.26	0.5	-0.64
Cash And Short Term Investments	0.93	0.78	0.3	-0.13	-0.4	-0.09	0.77	-0.35	0.52	0.72	0.76	-0.19	0.94	-0.71	0.04	0.73	0.21	0.28		0.63	0.3	0.96	0.36	0.26	0.25	-0.15
Net Receivables	0.57	0.65	0.53	0.01	-0.52	-0.32	0.18	-0.52	0.78	0.79	0.16	-0.51	0.48	-0.77	0.27	0.75	-0.14	0.51	0.63		0.44	0.56	0.07	0.88	0.63	-0.57
Common Stock Total Equity	0.31	0.4	0.15	-0.1	-0.37	-0.02	0.02	-0.38	0.6	0.4	0.01	-0.5	0.1	-0.68	-0.09	0.68	-0.39	0.41	0.3	0.44		0.09	-0.17	0.24	0.55	-0.58
Short Term Investments	0.89	0.7	0.27	-0.12	-0.25	-0.09	0.81	-0.21	0.38	0.68	0.78	-0.03	0.96	-0.52	0.12	0.54	0.36	0.12	0.96	0.56	0.09		0.43	0.25	0.13	0.02
Non Current Liabilities Total	0.05	-0.28	0.72	0.28	-0.28	-0.72	0.59	-0.18	-0.23	0.16	0.7	0.07	0.47	-0.06	0.35	0.03	0.15	0.09	0.36	0.07	-0.17	0.43		-0.19	-0.3	0.1
Inventory	0.29	0.45	0.34	-0.07	-0.31	-0.21	-0.13	-0.36	0.66	0.6	-0.18	-0.43	0.14	-0.52	0.31	0.5	-0.2	0.26	0.26	0.88	0.24	0.25	-0.19		0.58	-0.45
Other Current Assets	0.36	0.46	0.02	0.02	-0.35	0.13	0.03	-0.31	0.77	0.51	-0.03	-0.45	0.16	-0.66	-0.23	0.67	-0.36	0.5	0.25	0.63	0.55	0.13	-0.3	0.58		-0.5
Property Plant And Equipment Gross	-0.08	-0.25	-0.48	-0.01	0.51	0.39	0.25	0.51	-0.56	-0.34	0.21	0.55	-0.03	0.6	-0.08	-0.57	0.42	-0.64	-0.15	-0.57	-0.58	0.02	0.1	-0.45	-0.5

Click cells to compare fundamentals

Yield10 Bioscience Account Relationship Matchups

Yield10 Bioscience balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	16.7M	14.5M	20.4M	8.1M	3.9M	3.7M
Total Stockholder Equity	(4.1M)	9.5M	16.0M	4.4M	(2.5M)	(2.4M)
Retained Earnings	(364.9M)	(375.1M)	(386.1M)	(399.7M)	(414.2M)	(393.4M)
Other Assets	650K	3.3M	547K	331K	380.7K	361.6K
Common Stock Shares Outstanding	365.0K	2.4M	4.7M	4.9M	7.9M	8.3M
Liabilities And Stockholders Equity	16.7M	14.5M	20.4M	8.1M	3.9M	3.7M
Other Stockholder Equity	344.2M	370.2M	402.3M	404.3M	411.8M	282.7M
Total Liab	20.8M	5.0M	4.4M	3.7M	6.4M	6.1M
Short Long Term Debt Total	4.2M	3.6M	3.2M	2.7M	3.2M	2.9M
Other Current Liab	1.3M	1.3M	1.1M	926K	2.0M	2.1M
Total Current Liabilities	2.2M	1.8M	1.7M	1.6M	4.9M	3.0M
Other Liab	935K	15.0M	13K	7K	6.3K	6.0K
Property Plant And Equipment Net	4.4M	3.6M	3.2M	2.7M	2.2M	2.3M
Net Debt	(1.2M)	197K	(2.2M)	294K	2.1M	2.2M
Accounts Payable	279K	60K	83K	109K	1.2M	1.3M
Cash	5.4M	3.4M	5.3M	2.4M	1.1M	1.0M
Non Current Assets Total	5.0M	4.2M	3.8M	3.1M	2.5M	2.9M
Non Currrent Assets Other	432K	318K	283K	67K	42K	39.9K
Cash And Short Term Investments	11.1M	9.7M	16.0M	4.3M	1.1M	1.0M
Net Receivables	92K	113K	198K	30K	27K	25.7K
Common Stock Total Equity	91K	100K	9K	33K	38.0K	36.1K
Non Current Liabilities Total	18.6M	3.2M	2.7M	2.1M	1.5M	1.4M
Other Current Assets	475K	527K	436K	641K	332K	315.4K
Property Plant And Equipment Gross	4.4M	3.6M	3.2M	2.7M	3.7M	2.2M
Total Current Assets	11.7M	10.3M	16.6M	5.0M	1.4M	1.3M
Accumulated Other Comprehensive Income	(126K)	(159K)	(175K)	(229K)	(265K)	(278.3K)
Short Term Debt	602K	457K	514K	575K	1.7M	1.7M
Common Stock	100K	9K	33K	49K	120K	185.2K
Property Plant Equipment	1.2M	3.6M	3.2M	2.7M	2.5M	1.9M
Net Tangible Assets	(4.1M)	9.5M	16.0M	4.4M	4.0M	3.8M
Retained Earnings Total Equity	(342.8M)	(351.9M)	(364.9M)	(375.1M)	(337.6M)	(354.5M)
Capital Surpluse	355.4M	357.6M	360.9M	384.8M	442.5M	365.5M
Non Current Liabilities Other	935K	18.6M	13K	7K	8.1K	7.6K
Capital Lease Obligations	4.2M	3.8M	3.2M	2.7M	2.2M	2.6M
Net Invested Capital	(4.1M)	9.5M	16.0M	4.4M	(1.5M)	(1.4M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
GM	General Motors
V	Visa Class A

When determining whether Yield10 Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Yield10 Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Yield10 Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Yield10 Bioscience Stock:

How To Invest In Yield10

Details

Is Yield10 Stock a good investment?

Details

What is Yield10 Bioscience's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Yield10 Stock, please use our How to Invest in Yield10 Bioscience guide.

Note that the Yield10 Bioscience information on this page should be used as a complementary analysis to other Yield10 Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Yield10 Stock analysis

When running Yield10 Bioscience's price analysis, check to measure Yield10 Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Yield10 Bioscience is operating at the current time. Most of Yield10 Bioscience's value examination focuses on studying past and present price action to predict the probability of Yield10 Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Yield10 Bioscience's price. Additionally, you may evaluate how the addition of Yield10 Bioscience to your portfolios can decrease your overall portfolio volatility.

	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing

Is Yield10 Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.82)

Revenue Per Share

0.008

Quarterly Revenue Growth

(1.00)

Return On Assets

(1.50)

Return On Equity

(15.08)

The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Yield10 Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Yield10 Historical Balance Sheet

Yield10 Bioscience Inventory

0.86

About Yield10 Balance Sheet Analysis

Yield10 Bioscience Balance Sheet Chart

Common Stock Shares Outstanding

Total Liab

Yield10 Bioscience balance sheet Correlations

Yield10 Bioscience Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Yield10 Bioscience balance sheet Accounts

Also Currently Popular

Complementary Tools for Yield10 Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Liab	+ 0.98	Total Liab
Short Term Investments	+ 0.96	Current Deferred Revenue
Short Term Investments	+ 0.96	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.94	Current Deferred Revenue
Cash And Short Term Investments	+ 0.93	Total Assets
Property Plant And Equipment Net	+ 0.93	Short Long Term Debt Total

Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.93	Retained Earnings
Net Debt	- 0.86	Other Current Liab
Net Receivables	- 0.77	Net Debt
Net Debt	- 0.73	Total Current Liabilities
Non Currrent Assets Other	- 0.73	Common Stock Shares Outstanding